• Главная
  • NEW DAY MEDICINE
  • 3 (89) 2026
  • 40 -3 (89) 2026 - Abidova I.Kh., Yuldasheva D.Kh. - ASSESSMENT OF GUT MICROBIOCENOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE USING CLINICAL-LABORATORY AND MOLECULAR-GENETIC MARKERS

40 -3 (89) 2026 - Abidova I.Kh., Yuldasheva D.Kh. - ASSESSMENT OF GUT MICROBIOCENOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE USING CLINICAL-LABORATORY AND MOLECULAR-GENETIC MARKERS

ASSESSMENT OF GUT MICROBIOCENOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE USING CLINICAL-LABORATORY AND MOLECULAR-GENETIC MARKERS

Abidova I.Kh. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Yuldasheva D.Kh. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The study investigated gut microbiocenosis and IL-6 (rs1800795) genetic polymorphism in non-alcoholic fatty liver disease (NAFLD). A total of 100 NAFLD patients and 60 healthy controls were included. Gut microbiota was assessed using bacteriological and PCR methods, and IL-6 genotyping was performed by PCR-RFLP. NAFLD patients showed reduced bifidobacteria and lactobacilli, and increased conditional-pathogenic flora. IL-6 rs1800795 C allele and CC genotype increased disease risk and positively correlated with ALT and CRP. The results indicate that dysbiosis and genetic factors play a significant role in NAFLD pathogenesis, being important for diagnosis and personalized therapy. This study provides insights into integrating microbiocenosis and IL-6 genetic data for prevention and management of NAFLD.

Keywords: Non-alcoholic fatty liver disease, gut microbiocenosis, IL-6, genetic polymorphism, dysbiosis, ALT, CRP, clinical significance.

First page

248

Last page

251

For citation:Abidova I.Kh., Yuldasheva D.Kh. - ASSESSMENT OF GUT MICROBIOCENOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE USING CLINICAL-LABORATORY AND MOLECULAR-GENETIC MARKERS//New Day in Medicine 3(89)2026 248-251 https://newdayworldmedicine.com/en/new_day_medicine/3-89-2026

List of References

  1. Tilg H, Moschen AR. Gut–liver axis in non-alcoholic fatty liver disease. J Hepatol. 2020;73(2):328–339. doi:10.1016/j.jhep.2020.04.003.
  2. Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. Hepatology. 2016;63(3):764–775. doi:10.1002/hep.28356.
  3. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–873. doi:10.1016/j.jhep.2017.06.003.
  4. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction–associated fatty liver disease. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039.
  5. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–425. doi:10.1038/nrgastro.2016.85.
  6. Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD. Nat Rev Gastroenterol Hepatol. 2020;17(5):279–297. doi:10.1038/s41575-020-0269-9.
  7. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513–1524. doi:10.1053/j.gastro.2014.01.020.
  8. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13):1546–1558. doi:10.2174/138161209788168164.
  9. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007;449(7164):804–810. doi:10.1038/nature06244.
  10. Zhang Y, Guo X, Li J, et al. Association between IL-6 polymorphisms and metabolic syndrome. Cytokine. 2015;76(2):322–328. doi:10.1016/j.cyto.2015.06.025.

    file

    download